Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. Research shows it enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. Clinical studies, such as the STEP 1 trial, demonstrated an average 14.9% reduction in body weight over 68 weeks with semaglutide 2.4 mg weekly.
Black Pearl Labs provides semaglutide at research-grade purity for laboratory use only. Not for human consumption.
Black Pearl Labs sells products intended for research and laboratory use only.
Products are not for human or animal consumption and are not approved for diagnostic, therapeutic, or clinical use.
By entering this website, you confirm that: